)
Heartbeam (BEAT) investor relations material
Heartbeam Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Heart attack assessment became the primary strategic focus, with FDA Breakthrough Device Designation, TAP acceptance and agreement on a 510(k) pathway advancing the program.
ALIGN-ACS showed comparable HeartBeam 3D ECG accuracy to standard 12-lead ECG; a U.S. pivotal study is planned to begin in Q1 2027.
Q3 losses, expenses and cash use declined; approximately $4.0M of Q4 ATM proceeds lifted unaudited pro forma cash to $10.1M.
The FDA-cleared system is limited to arrhythmia assessment; heart attack detection and AI applications remain investigational.
Financial highlights
Q3 operating expenses were $3.457M, down from $5.092M in Q2 2026 and $5.290M in Q3 2025; net loss was $3.010M versus $5.039M and $5.255M, respectively.
Q3 net loss per share was $0.05 versus $0.10 in Q2 2026 and $0.15 in Q3 2025; nine-month net loss was $12.749M versus $15.713M.
Nine-month operating expenses were $13.265M versus $15.829M; R&D was $6.816M versus $10.096M, while SG&A was $6.449M versus $5.733M.
No revenue was generated through September 30, 2026; no material commercial revenue is expected in 2026.
Outlook and guidance
FY2026 net operating cash outflow guidance is $12.0M–$12.5M, reduced from prior guidance of less than $14M; baseline Q4 operating cash outflow is expected below $2.5M.
Pivotal-study design is targeted for completion in Q4 2026, with enrollment planned for Q1 2027 and completion targeted by mid-2027; accelerated timing could increase Q4 spending.
Management described a likely pivotal study of about 300 patients across 8–10 centers; FDA agreement on study size and endpoints remains pending.
- Commercial launch is underway as clinical studies advance a broader cardiac platform opportunity.BEAT
Investor presentation - Clinical and commercial progress accelerated, cash runway extended, but liquidity risks remain.BEAT
Q2 2026 - Directors and auditor approved; equity plan amendment failed; updates set for August.BEAT
AGM 2026 - Two board nominees, including the CEO, have withdrawn from re-election with no replacements named.BEAT
Proxy filing - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - FDA-cleared at-home 12-lead ECG platform targets $40B market with scalable, AI-driven growth.BEAT
Investor presentation - Annual meeting to elect directors, ratify auditor, and expand equity plan by 3 million shares.BEAT
Proxy filing - Net loss narrowed, cash burn fell, and $11.5M funding supports clinical and commercial growth.BEAT
Q1 2026 - AIMIGo nears FDA clearance as Q2 loss hits $5M, cash burn raises going concern risk.BEAT
Q2 2024
)
)
)
)
)
)
)
)